Search results for "Ketamine"

showing 8 items of 38 documents

Ketamīna lietošana kompleksā reģionālā sāpju sindroma (CRPS) ārstēšanā

2022

Nosaukums: Ketamīna lietošana kompleksā reģionālā sāpju sindroma (CRPS) ārstēšanā Autors: Serge Alan Johansson Darba vadītāja: Iveta Golubovska, Dr. Med. Anesteziologs, reanimatologs un algologs Priekšvēsture: Kompleksais reģionālais sāpju sindroms (CRPS) ir slikti izprasts stāvoklis, kad cilvēkam ir ilgstošas smagas un neciešamas sāpes. Lai gan lielā daļa CRPS gadījumu ir ievainojumu izraisīti, no tā izrietošās sāpes ir ilgstošas un intensīvas. Mērķi: Šī darba mērķis ir izpētīt ketamīna ietekmi uz CRPS ārstēšanu, salīdzinot Numerisko sāpju skalu (NRS) un Analgēzijas nocicepcijas indeksu (ANI). Materiāli un metodes: Pētījums tika veikts, ievadot nelielu Ketamīna devu 25 mg i.v. un novērtējo…

algologyANIKetaminepainCRPSMedicīna
researchProduct

Analgesic Effect of Intravenous Ketamine in Cancer Patients on Morphine Therapy

2000

Pain not responsive to morphine is often problematic. Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure…

business.industryAnalgesicCrossover studyAnesthesiology and Pain MedicineBolus (medicine)OpioidAnesthesiaNeuropathic painmedicineMorphineKetamineNeurology (clinical)businessCancer painGeneral Nursingmedicine.drugJournal of Pain and Symptom Management
researchProduct

Manejo perioperatorio del dolor en el paciente en tratamiento crónico con opiáceos

2011

Pain is one of the most common reasons for seeking medical care and the frequency of prescription of opioid analgesics by both primary care physicians and specialists has increased. It is therefore unsurprising that many patients with chronic pain who must undergo scheduled or emergency surgery will be on long-term medication, including opioids. Managing postoperative pain, even with high doses of drugs, seems to be more difficult in regular users of such analgesics, possibly because of an apparent association of opioid use with increased tolerance and hyperalgesia. Postoperative pain relief should be carefully tailored in these cases by means of a management plan worked out along with the …

business.industryChronic painMEDLINEPrimary careCritical Care and Intensive Care Medicinemedicine.diseaseAnesthesiology and Pain MedicineEmergency surgeryRegional anesthesiaAnesthesiaHyperalgesiamedicineKetaminemedicine.symptomMedical prescriptionbusinessmedicine.drugRevista Española de Anestesiología y Reanimación
researchProduct

Data from: NMDA receptor antagonists and pain relief: a meta-analysis of experimental trials

2019

OBJECTIVES: We conducted a meta-analysis of controlled trials that used experimental models of acute pain and hyperalgesia to examine the analgesic effects of N-methyl-D-aspartate receptor (NMDAR) antagonists. METHODS: Six major databases were systematically searched (to 03/2018) for studies using human evoked pain models to compare NMDAR antagonists with no-intervention controls. Pain outcome data were analyzed with random-effects meta-analysis. RESULTS: Searches identified 70 eligible trials (N=1069). Meta-analysis found that low-dose ketamine (<1 mg/kg) produced a decrease in the size of hyperalgesic area (Standardized Mean Difference=0.54, CI95[0.34, 0.74], p<.001), and a 1.2-poin…

medicine and health caredextromethorphanketamineNMDAMedicineReviewAnalgesiaLife sciences
researchProduct

Complex regional pain syndrome: An optimistic perspective.

2014

Complex regional pain syndrome (CRPS) presents with clinical symptoms that can no longer be explained by the initial trauma, including pain, sensory, motor, and trophic symptoms, and impairment of autonomic control of the limb. These symptoms spread distally and go beyond single nerve innervation territories. Typically, the symptoms change through the course of CRPS as a result of the varying pathophysiology. Diagnosis is made clinically after the rigorous elimination of other possible causes, and 3-phase bone scintigraphy can be a useful tool for confirming CRPS. In acute stages, inflammatory symptoms prevail and should be treated with anti-inflammatory agents (steroids), bisphosphonates, …

medicine.medical_specialtyImagery PsychotherapyImplosive TherapyPainMotor imageryOccupational TherapyNeuroplasticitymedicineHumansKetamineGlucocorticoidsPhysical Therapy ModalitiesAnalgesicsmedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industrySensory lossmedicine.diseaseComorbidityComplex regional pain syndromeBone scintigraphyAutonomic Nervous System DiseasesHyperalgesiaHyperalgesiaPhysical therapyKetamineNeurology (clinical)medicine.symptombusinessComplex Regional Pain Syndromesmedicine.drugNeurology
researchProduct

Analgosedierungsverfahren f�r zahn�rztlich-chirurgische Eingriffe mit Midazolam/Pentazocin und Midazolam/Ketamin Klinische Doppelblindstudie zu Anxio…

1995

Ketamin/Midazolam zur Analgosedierung erwies sich in bezug auf Kreislauf und Atmung gegenuber Pentazocin/Midazolam uberlegen [23]. Diese Studie sollte klaren, ob 0,25 oder 0,5 mg/kg KG Ketamin, 0,075 mg/kg KG Midazolam, unter den Aspekten Anxiolyse, Analgesie, Sedierung und Amnesie eine Alternative zu Pentazocin/Midazolam ist. Kontrollgruppe (KG): Lokalanasthesie (LA) mit Articain 4%/Adrenalinzusatz 1:200.000 (n=35); Testgruppe P/M: LA und 0,40 mg/kg KG Pentazocin/0,075 mg/kg KG Midazolam i.v. (n=35); Testgruppe K25/M: LA und 0,25 mg/kg KG Ketamin/0,075 mg/kg KG Midazolam i.v. (n=35); Testgruppe K50/M: LA und 0,50 mg/kg KG Ketamin/0,075 mg/kg KG Midazolam i.v. (n=35). Die LA wurde 3 min nac…

medicine.medical_specialtybusiness.industrySedationGeneral MedicinePentazocinSurgeryDouble blind studyAnesthesiology and Pain MedicinePentazocineFace surgeryAnesthesiamedicineMidazolamKetaminemedicine.symptombusinessmedicine.drugDer Anaesthesist
researchProduct

Sedation During Neurocritical Care

2019

AbstractSedation is an essential therapeutic strategy in the care of neurocritical patients. Intravenous sedative agents are the most widely used, with promising alternatives (dexmedetomidine, ketamine, and volatile agents) to propofol and midazolam arising. Studies designed to evaluate superiority and avoid biases are required. A neurological awakening test is safe in most patients. Potential risks and benefits of limiting deep sedation and daily interruption of sedation in these patients remain unclear. The aim of this review was to report recent clinical evidence on sedation in this subgroup of patients, focusing on its effects on clinical prognosis.

medicine.medical_specialtymedicine.drug_classSedationCritical Care and Intensive Care Medicinelcsh:RD78.3-87.303 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineKetamineDexmedetomidineIntensive care medicinebusiness.industryNeurointensive careneurointensive care unitReview articleneurological wakeup testAnesthesiology and Pain Medicineneurocritical carelcsh:AnesthesiologySedativesedative agentsMidazolamNeurology (clinical)medicine.symptombusinessPropofol030217 neurology & neurosurgerymedicine.drugJournal of Neuroanaesthesiology and Critical Care
researchProduct

NMDA receptor antagonists and pain relief: A meta-analysis of experimental trials

2019

ObjectiveWe conducted a meta-analysis of controlled trials that used experimental models of acute pain and hyperalgesia to examine the analgesic effects of NMDA receptor (NMDAR) antagonists.MethodsSix major databases were systematically searched (to March 2018) for studies using human evoked pain models to compare NMDAR antagonists with no-intervention controls. Pain outcome data were analyzed with random-effects meta-analysis.ResultsSearches identified 70 eligible trials (n = 1,069). Meta-analysis found that low-dose ketamine (<1 mg/kg) produced a decrease in hyperalgesic area (standardized mean difference 0.54, 95% confidence interval [CI] 0.34, 0.74, p < 0.001) and a 1.2-point decr…

pain NMDA ketamine dextromethorphan analgesia review meta-analysisAnalgesicPain reliefDextromethorphanReceptors N-Methyl-D-Aspartate03 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineHumansKetamineAcute painbusiness.industryChronic painModels Theoreticalmedicine.diseaseAcute PainHyperalgesiaAnesthesiaMeta-analysisHyperalgesiaRC0321NMDA receptorKetamineNeurology (clinical)medicine.symptombusinessExcitatory Amino Acid Antagonists030217 neurology & neurosurgerymedicine.drug
researchProduct